Latest news

August 17, 2022 Experience the JUVÉDERM® Difference with Allergan Aesthetics
August 03, 2022 FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition
July 29, 2022 AbbVie Reports Second-Quarter 2022 Financial Results
Looking for more news from AbbVie?
Follow us onsocial media.

Quick links

Fact sheet

See a high-level overview about our business.

Image library

Our media library provides you with our official AbbVie media including our logo, building and leaders.

Subscribe

Stay up to date on recent news, articles, and more.

Filter by categories




All news

April 13, 2022
BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval
April 12, 2022
AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis
April 05, 2022
Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia)
March 29, 2022
Laura Schumacher Announced as Recipient of ABA’s 2022 Margaret Brent Award
March 29, 2022
AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting
March 29, 2022
Allergan Aesthetics Brings Data, Innovation & Industry Expertise to the 2022 Aesthetic and Anti-aging Medicine World Congress (AMWC)
March 21, 2022
AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting
March 16, 2022
RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
March 15, 2022
Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours
March 15, 2022
AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19

More information

Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact.Learn more

Societal impact

Our commitment to science is a commitment to better our society.Read our 2021 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry.Learn more

Annual report

See our latest 2021 Annual Report on Form 10-K.Learn more

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, pleaseupdate your user profileand check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?